Acumen Pharmaceuticals (NASDAQ: ABOS) has identified 2026 as a pivotal catalyst year as it advances its lead Alzheimer’s candidate, sabirnetug, through Phase II trials. The company is simultaneously leveraging a strategic partnership with JCR Pharmaceuticals to implement enhanced brain delivery (EBD) technology, aiming to overcome the blood-brain barrier challenges that have historically hindered neurodegenerative treatments.
About Alzheimer's disease coverage
This page surfaces every story mentioning Alzheimer's disease across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
What you see
What it tells you
Story count
Number of distinct stories where Alzheimer's disease was a primary or referenced actor.
Recency clustering
Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distribution
Aggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche links
When the same entity surfaces in our sibling networks, we link to those views to enrich context.